

ALEXION PHARMACEUTICALS INC  
Form 8-K/A  
March 22, 2004

---

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

## FORM 8-K/A

### Amendment No. 2

#### CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) December 18, 2003

---

## ALEXION PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware  
(State or Other Jurisdiction

0-27756  
(Commission

13-3648318  
(IRS Employer

of Incorporation)

File Number)

Identification No.)

352 Knotter Drive, Cheshire, CT  
(Address of Principal Executive Offices)

06410  
(Zip Code)

Registrant's telephone number, including area code: (203) 272-2596

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

---

**Item 5. Other Events and Regulation FD Disclosure.**

This Amendment No. 2 relates to the Company's Current Report on Form 8-K filed on December 18, 2003 and Amendment No. 1 thereto filed on January 9, 2004. The purpose of this amendment is to update Item 7(c).

On December 18, 2003, the Company announced its entry into a collaborative agreement with XOMA Ltd. (the Agreement) for the development and commercialization of a rationally designed human c-MPL agonist antibody to treat chemotherapy-induced thrombocytopenia.

On January 9, 2004, the Company filed with the Securities and Exchange Commission an application for confidential treatment of certain portions of the Agreement.

On March 22, 2004, the Company filed a revised application for confidential treatment of certain portions of the Agreement. A copy of the Agreement, with the confidential portions redacted, is filed herewith.

**Item 7. Financial Statements and Exhibits.**

**(c) Exhibits.**

- |       |   |
|-------|---|
| 10.28 | Co-Development and Co-Commercialization Agreement between Alexion Pharmaceuticals, Inc. and XOMA (US) LLC, dated as of December 17, 2003 (with certain confidential information omitted, which omitted information is the subject of a revised confidential treatment request and has been filed separately with the Securities and Exchange Commission). |
| 99.1  | Press Release dated December 18, 2003.*   |

---

\* Previously filed

